Design Therapeutics, Inc. - Common Stock — movimiento de fondos (NASDAQ:DSGN) | MetaTrader

Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas

Flujo de caja de las actividades operativas -29.38 M-51.32 M-58.56 M-43.1 M-54.36 M -54 M Flujo de caja de las actividades de inversión -53.64 M-220.99 M52.54 M43.95 M22.91 M 7.45 M Flujo de caja de las actividades financieras 379.21 M235 K724 K513 K25.74 M 45.65 M Flujo de caja libre -29.38 M-51.32 M-58.56 M-43.1 M-54.55 M -54.12 M

Noticias

FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer

AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Design Therapeutics (NASDAQ:DSGN)

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

RBC Capital eleva el precio objetivo de Design Therapeutics tras datos del ensayo

Design Therapeutics presenta datos del ensayo de fase 1/2 de DT-216P2 en ataxia de Friedreich

Las acciones de Design Therapeutics se disparan tras datos positivos del ensayo

Design Therapeutics presenta datos positivos de ensayo para el tratamiento de la AF

Cramer: Design Therapeutics Is ‘Pure Spec,’ Buy This Health Care Stock - BillionToOne (NASDAQ:BLLN), Desi

Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know

Design Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:DSGN) 2026-04-30